90
Participants
Start Date
November 30, 2025
Primary Completion Date
November 30, 2030
Study Completion Date
November 30, 2030
Atezolizumab and Bevacizumab
"Participants will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31) until surgery or unacceptable toxicity, whichever occurs first (neoadjuvant therapy).~The adjuvant therapy with Atezo + Bev will start between 4 and 12 weeks after the resection date, once the participant has fully recovered from the surgery. Participants will receive up to 12 months or 17 cycles of treatment, whichever occurs first, or until disease recurrence or unacceptable toxicity."
Hospital Universitario Reina Sofía, Córdoba
Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela
Hospital Universitari Josep Trueta, Girona
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario Virgen de la Victoria, Puerto de la Torre
Hospital Universitario Marqués de Valdecilla, Santander
Hospital Universitario y Politécnico La Fe, Valencia
Hospital Universitario de Cruces, Barakaldo
Hospital Universitari Germans Trias i Pujol, Badalona
Hospital Universitari de Bellvitge, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Fundacion Clinic per a la Recerca Biomédica
OTHER